Hiremon (Propofol)

Hiremon is indicated for procedures that require rapid onset of unconsciousness or moderate sedation. It is commonly employed in operating rooms, intensive care units, and diagnostic settings.

• Induction of general anesthesia for surgical procedures.
• Maintenance of anesthesia during short‑duration surgeries.
• Procedural sedation for endoscopic or bronchoscopic examinations.
• Sedation of mechanically ventilated patients in intensive care.
• Adjunctive sedation for diagnostic imaging requiring patient immobility.
• Recovery phase support when rapid emergence is desired.

• Propofol, the active component of Hiremon, produces its anesthetic effect by enhancing the activity of the γ‑aminobutyric acid type A (GABA_A) receptor. Binding to the receptor’s β‑subunit increases chloride ion influx, leading to hyperpolarization of neuronal membranes and reduced excitatory neurotransmission. This potentiation results in rapid onset of sedation, hypnosis, and loss of consciousness, while also providing dose‑dependent amnestic properties.

Like other intravenous anesthetics, Hiremon may be associated with a range of adverse reactions that vary in frequency and severity. These events are monitored closely during administration.

Common

• Transient pain or burning sensation at the injection site.
• Mild hypotension or decreased blood pressure.
• Brief episodes of bradycardia (slow heart rate).
• Respiratory depression that resolves with reduced infusion rate.
• Nausea or vomiting during emergence.
• Dizziness or feeling of lightheadedness.
• Transient visual disturbances such as blurred vision.
• Temporary decrease in body temperature.

Serious

• Prolonged apnea requiring airway support.
• Severe hypotension leading to organ hypoperfusion.
• Allergic reactions such as anaphylaxis or skin rash.
• Cardiac arrhythmias such as ventricular ectopy.
• Myoclonus or involuntary muscle movements.

When using Hiremon, clinicians should observe specific precautions to minimize risk and ensure patient safety.

• Verify patient identity and confirm a valid prescription before administration.
• Assess cardiovascular status, especially for patients with unstable blood pressure or heart disease.
• Perform a thorough airway evaluation to anticipate potential respiratory compromise.
• Use appropriate monitoring equipment, including pulse oximetry, ECG, and blood pressure cuffs throughout the procedure.
• Adjust infusion rates in elderly or frail patients due to increased sensitivity.
• Avoid use in patients with known hypersensitivity to propofol or its formulation components.

Hiremon can interact with other medications, potentially altering its anesthetic profile or affecting patient safety.

Avoid

• Concurrent use of other central nervous system depressants such as benzodiazepines, opioids, or barbiturates.
• Co‑administration with potent vasodilators that may exacerbate hypotension.
• Simultaneous infusion of lipid‑based parenteral nutrition solutions that could affect propofol clearance.
• Concurrent use of high-dose catecholamines, which may increase the risk of arrhythmias.

Use with caution

• Anticholinergic agents, which may increase heart rate and mask bradycardia.
• Inhalational anesthetics, requiring careful titration to avoid excessive sedation.
• Medications that inhibit cytochrome P450 enzymes (e.g., CYP2B6 inhibitors), potentially prolonging propofol effects.
• Drugs that alter serum lipid levels, as propofol is formulated in a lipid emulsion.